Movement Alert|GenScript Biotech Rises 5.07% in Regular Trading, AI Drug Discovery Theme Drives Sector-Wide Rally

Market Focus07-06

On July 6, GenScript Biotech rose 5.07% in regular trading, trading at HK$14.44/share, with turnover of approximately HK$117 million. The rally was driven by sustained market enthusiasm for the AI-powered drug discovery sector, with GenScript positioned as a foundational infrastructure service provider in the AI drug discovery value chain.

On the news front, market attention toward AI drug discovery has continued to intensify in recent days. As a gene synthesis and life sciences tools platform company, GenScript has attracted capital inflows due to its role in providing wet-lab experimental services essential to AI-designed molecule validation. Reports indicate that ByteDance's AI drug discovery entity, AnewTherapeutics, has registered in Singapore, further boosting expectations for an explosion in demand for wet-lab experiment services supporting AI-driven drug development.

Within the Life Sciences Tools and Services sector, other stocks also showed positive movement, with Wuxi XDC up 4.13%, XtalPi up 4.05%, Wuxi Biologics up 2.18%, Insilico Medicine up 1.61%, and Wuxi AppTec up 1.41%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment